315 related articles for article (PubMed ID: 31677889)
1. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.
Coccia F; Testa M; Guarisco G; Bonci E; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
Endocrine; 2020 Mar; 67(3):569-578. PubMed ID: 31858390
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease.
Pacifico L; Di Martino M; Anania C; Andreoli GM; Bezzi M; Catalano C; Chiesa C
World J Gastroenterol; 2015 Apr; 21(15):4688-95. PubMed ID: 25914480
[TBL] [Abstract][Full Text] [Related]
4. Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features.
Cazzo E; Jimenez LS; Gestic MA; Utrini MP; Chaim FHM; Chaim FDM; Pareja JC; Chaim EA
Obes Surg; 2018 Jan; 28(1):187-194. PubMed ID: 28741239
[TBL] [Abstract][Full Text] [Related]
5. Insulin Resistance, but Not Obstructive Sleep Apnea Is Associated with Hepatic Steatosis in Chinese Patients with Severe Obesity.
Zhu C; Tang S; Xiao J; Zhang Y; Sun L; Zhang J; Ding L; Liu M
Obes Facts; 2023; 16(4):344-355. PubMed ID: 36854279
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for increased risk of diabetes in chronic liver diseases.
Svegliati-Baroni G; Gaggini M; Carli F; Barbieri C; Cucco M; Youne R; Rosso C; Bugianesi E; Gastaldelli A
Liver Int; 2020 Oct; 40(10):2489-2499. PubMed ID: 32515880
[TBL] [Abstract][Full Text] [Related]
7. Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤ 6.4% in Japan.
Matsumoto N; Arase Y; Kawamura Y; Ohmoto-Sekine M; Amakawa K; Ogawa K; Tsuji H; Dong HS; Hara S; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Kumada H; Kobayashi T
Intern Med; 2015; 54(8):875-80. PubMed ID: 25876566
[TBL] [Abstract][Full Text] [Related]
8. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
9. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitivity indices: fasting versus glucose-stimulated ındices in pediatric non-alcoholic fatty liver disease.
Ozhan B; Ersoy B; Kiremitci S; Ozkol M; Taneli F
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3450-8. PubMed ID: 26439042
[TBL] [Abstract][Full Text] [Related]
11. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
12. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
Barb D; Bril F; Kalavalapalli S; Cusi K
J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
[TBL] [Abstract][Full Text] [Related]
13. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.
Sesti G; Fiorentino TV; Hribal ML; Sciacqua A; Perticone F
Nutr Metab Cardiovasc Dis; 2013 Dec; 23(12):1182-7. PubMed ID: 23419734
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
15. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
16. Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring.
Oki Y; Ono M; Hyogo H; Ochi T; Munekage K; Nozaki Y; Hirose A; Masuda K; Mizuta H; Okamoto N; Saibara T
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):797-805. PubMed ID: 29634665
[TBL] [Abstract][Full Text] [Related]
17. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2014 Oct; 100(5):. PubMed ID: 25303488
[TBL] [Abstract][Full Text] [Related]
18. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.
Liew PL; Lee WJ; Wang W; Lee YC; Chen WY; Fang CL; Huang MT
Obes Surg; 2008 Jul; 18(7):847-53. PubMed ID: 18459024
[TBL] [Abstract][Full Text] [Related]
19. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
Sterling RK; Smith PG; Brunt EM
J Clin Gastroenterol; 2013 Feb; 47(2):182-7. PubMed ID: 23059409
[TBL] [Abstract][Full Text] [Related]
20. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
